These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25230982)

  • 1. Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non-renal cancer model.
    Zatovicova M; Jelenska L; Hulikova A; Ditte P; Ditte Z; Csaderova L; Svastova E; Schmalix W; Boettger V; Bevan P; Pastorek J; Pastorekova S
    Int J Oncol; 2014 Dec; 45(6):2455-67. PubMed ID: 25230982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain.
    Zatovicova M; Jelenska L; Hulikova A; Csaderova L; Ditte Z; Ditte P; Goliasova T; Pastorek J; Pastorekova S
    Curr Pharm Des; 2010; 16(29):3255-63. PubMed ID: 20819068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma.
    Chrastina A; Závada J; Parkkila S; Kaluz S; Kaluzová M; Rajcáni J; Pastorek J; Pastoreková S
    Int J Cancer; 2003 Jul; 105(6):873-81. PubMed ID: 12767076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G250: a carbonic anhydrase IX monoclonal antibody.
    Lam JS; Pantuck AJ; Belldegrun AS; Figlin RA
    Curr Oncol Rep; 2005 Mar; 7(2):109-15. PubMed ID: 15717944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma.
    Brouwers AH; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    Cancer Biother Radiopharm; 2003 Aug; 18(4):539-47. PubMed ID: 14503948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
    Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
    Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.
    Lawrentschuk N; Lee FT; Jones G; Rigopoulos A; Mountain A; O'Keefe G; Papenfuss AT; Bolton DM; Davis ID; Scott AM
    Urol Oncol; 2011; 29(4):411-20. PubMed ID: 19523858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX(G250/MN).
    Mulders P; Bleumer I; Debruyne F; Oosterwijk E
    Urologe A; 2004 Sep; 43 Suppl 3():S146-7. PubMed ID: 15164181
    [No Abstract]   [Full Text] [Related]  

  • 9. The novel CA IX inhibition antibody chKM4927 shows anti-tumor efficacy in vivo.
    Yamaguchi A; Usami K; Shimabe M; Hasegawa K; Asada M; Motoki K; Tahara T; Masuda K
    Anticancer Res; 2015 Apr; 35(4):1997-2004. PubMed ID: 25862852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas.
    Uemura H; Nakagawa Y; Yoshida K; Saga S; Yoshikawa K; Hirao Y; Oosterwijk E
    Br J Cancer; 1999 Oct; 81(4):741-6. PubMed ID: 10574265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX.
    Zat'ovicová M; Tarábková K; Svastová E; Gibadulinová A; Mucha V; Jakubícková L; Biesová Z; Rafajová M; Ortova Gut M; Parkkila S; Parkkila AK; Waheed A; Sly WS; Horak I; Pastorek J; Pastoreková S
    J Immunol Methods; 2003 Nov; 282(1-2):117-34. PubMed ID: 14604546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology.
    Xu C; Lo A; Yammanuru A; Tallarico AS; Brady K; Murakami A; Barteneva N; Zhu Q; Marasco WA
    PLoS One; 2010 Mar; 5(3):e9625. PubMed ID: 20224781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.
    Surfus JE; Hank JA; Oosterwijk E; Welt S; Lindstrom MJ; Albertini MR; Schiller JH; Sondel PM
    J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):184-91. PubMed ID: 8811493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-inducible expression of the mouse carbonic anhydrase IX demonstrated by new monoclonal antibodies.
    Takacova M; Barathova M; Hulikova A; Ohradanova A; Kopacek J; Parkkila S; Pastorek J; Pastorekova S; Zatovicova M
    Int J Oncol; 2007 Nov; 31(5):1103-10. PubMed ID: 17912436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-mediated endocytosis of G250 tumor-associated antigen allows targeted gene transfer to human renal cell carcinoma in vitro.
    Dürrbach A; Angevin E; Poncet P; Rouleau M; Chavanel G; Chapel A; Thierry D; Gorter A; Hirsch R; Charpentier B; Senik A; Hirsch F
    Cancer Gene Ther; 1999; 6(6):564-71. PubMed ID: 10608353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use.
    Pastorek J; Pastorekova S
    Semin Cancer Biol; 2015 Apr; 31():52-64. PubMed ID: 25117006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule.
    Honarvar H; Garousi J; Gunneriusson E; Höidén-Guthenberg I; Altai M; Widström C; Tolmachev V; Frejd FY
    Int J Oncol; 2015 Feb; 46(2):513-20. PubMed ID: 25434612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.
    Luiten RM; Coney LR; Fleuren GJ; Warnaar SO; Litvinov SV
    Br J Cancer; 1996 Sep; 74(5):735-44. PubMed ID: 8795576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbonic anhydrase IX expression in prostate cancer.
    Smyth LG; O'Hurley G; O'Grady A; Fitzpatrick JM; Kay E; Watson RW
    Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):178-81. PubMed ID: 20038959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A tumor targeted gene vector modified with G250 monoclonal antibody for gene therapy.
    Duan Y; Zheng J; Han S; Wu Y; Wang Y; Li D; Kong D; Yu Y
    J Control Release; 2008 Apr; 127(2):173-9. PubMed ID: 18316136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.